Tag: BioNTech

The German biotech firm BioNTech is decisively pivoting beyond its pandemic-era identity, placing a substantial strategic bet on mRNA oncology. ...

BioNTech has completed its takeover of CureVac, a move that solidifies its commanding position within Germany's mRNA therapeutics landscape. By ...

While BioNTech stock trades near its 52-week low, a significant shift is occurring behind the scenes. Prominent institutional investors are ...

For investors in BioNTech, the company's long-stated pivot beyond its COVID-19 vaccine foundation has awaited concrete validation. This week, the ...

While BioNTech SE achieved a major strategic objective this week, investor sentiment was dominated by emerging regulatory headwinds from the ...

December has opened with a jolt for BioNTech and its investors. A strategic pivot toward oncology and a critical acquisition ...

This week represents a pivotal moment for BioNTech SE, with events set to unfold that could fundamentally shape the biotech ...

The coming days represent a pivotal moment for BioNTech SE. The biotech firm is entering the final phase of its ...

BioNTech faces a pivotal week as significant corporate developments converge. The impending deadline for the CureVac acquisition coincides with substantial ...

The German biotech firm BioNTech finds itself at a pivotal moment. As the company navigates the final stages of its ...